Hospitals May Be Overcharging for Hip, Knee Replacements

Share this content:
Hospitals May Be Overcharging for Hip, Knee Replacements
Hospitals May Be Overcharging for Hip, Knee Replacements

WEDNESDAY, March 1, 2017 (HealthDay News) -- Some U.S. hospitals might be charging private insurers twice as much for knee and hip replacements as the implants typically cost, according to a research letter published in the Feb. 28 issue of the Journal of the American Medical Association.

Yi-Ju Tseng, Ph.D., and Kenneth Mandl, M.D., M.P.H., of the Computational Health Informatics Program at Boston Children's Hospital, looked at statistics from a single private insurance plan from 2011 to 2015. They focused on 40,372 patients with knee replacements and 23,570 patients with hip replacements. They compared the costs paid by the insurers for the implants to the average costs of the implants, as disclosed by a group of 160 hospitals and another group of 1,500 hospitals.

The researchers found that the insurer paid an average of $10,604.52 for knee implants and $11,751.25 for hip implants, along with related supplies. But the average cost of the implants and related supplies, as determined by the group of 160 hospitals, was $5,023.01 for knee and $5,619.75 for hip. The average prices for the other hospital group were similar.

The numbers suggest that insurers paid an average of $5,600 more for knee implants and $6,100 more for hip implants than the average prices, the study authors said. The authors noted that their research had limitations. It only looked at one insurer, and all the patients were under 65.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »